Table 3.

Presentation at the initial episode, management, and evolution

Patient	Creatinine level (μmol/l)	Proteinuria urine ACR (mg/mmol)	Serum albumin level (g/l)	MAHA	Management						Complications and outcome
					NA	Supportive	Dialysis (duration)	FFP	PEX	Eculizumab
NCL25	NA	NA	NA	NA	Yes	NA	No	NA	NA	No	NA
NCL26	NA	NA	NA	Yes	Yes	NA	NA	NA	NA	No	Spontaneous remission
NCL27	88	(1.58 g/24 h)	NA	NA	–	Yes	No	No	No	No	Recovery of renal function
NCL28	NA	NA	NA	NA	Yes	NA	NA	NA	NA	No	NA
NCL29	141	2660	NA	NA	–	Yes	Yes (17 d)	Yes (×7)	No	No	Recovery of renal function
NCL30	150	1268	23	Yes	–	Yes	No	No	No	No	Recovery of renal function
NCL31	165	>500	18	Yes	–	Yes	No	Yes	No	No	NA
NCL32	312	>500	15	Yes	–	Yes	Yes (9 mo)	Yes	No	No	NA
NCL33	210	NA	26	Yes	–	Yes	Yes (17 d)	No	No	No	Recovery of renal function
NCL34	1921	PCR 339a	32	Yes	–	Yes	Yes (12 d)	No	No	No	Recovery of renal function
NCL35	112	>500	23	Yes	–	Yes	No	Yes	No	No	NA
NCL36	68	PCR 2410b	25	Yes	–	Yes	Yes (12 d)	No	Yes	No	Partial recovery of renal function
NCL37	54	309	24	No	–	Yes steroid + ACEI	No	No	No	No	Remission
NCL38	145	3447	27	Yes	–	Yes	Yes (15 d)	Yes	Yes	No	Recovery Hypertensive heart failure and encephalopathy
NCL39	453	1836	17	Yes	–	Yes	Yes (15 d)	No	No	No	Spontaneous remission
NCL40	223	PCR 3857b	28	Yes	–	Yes	No	No	No	Yes	Remission

ACEI, angiotensin-converting enzyme inhibitor; ACR, albumin/creatinine ratio; FFP, fresh frozen plasma; MAHA, microangiopathic hemolytic anemia (anemia and schistocytes identified on blood film microscopy); NA, not available; PCR, protein/creatinine ratio; PEX, plasma exchange.

If proteinuria was not quantified at presentation, the earliest available sample is shown: ^a1 mo and ^b3 mo after presentation.